Appropriate models for novel osteoporosis drug discovery and future perspectives

Luigi Gennari, Stefano Rotatori, Simone Bianciardi, Stefano Gonnelli, Ranuccio Nuti, Daniela Merlotti

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Introduction: Osteoporosis is a common skeletal disorder characterized by compromised bone strength and increased fracture risk. It is becoming a growing health-economic problem worldwide. Over the past two decades, there has been considerable progress in the availability of compounds with antiresorptive or anabolic activity on bone. However, existing therapeutic strategies still have limitations.Areas covered: In this review, the authors summarize past and current approaches for the development of antiresorptive and anabolic agents for osteoporosis together with their mechanisms of action. They also provide discussion on the application of new technologies for novel osteoporosis drug discovery.Expert opinion: Thanks to the recent advances in molecular biology over the past few years, novel therapeutic targets for antiresorptive or anabolic compounds have been discovered and several promising new drugs are in preclinical and clinical development. Despite these advances, the current understanding of the mechanisms regulating bone remodeling is far from complete, leaving significant drawbacks to the discovery and the clinical development of novel therapeutic agents. Hopefully, improvements in functional genomics and bioinformatics, along with new technological approaches such as RNA silencing, quantitative proteomics, metabolomics, and the use of mesenchymal stem cells, will address these issues and widen our options for treating several disorders of bone metabolism, including osteoporosis.

Original languageEnglish
Pages (from-to)1201-1216
Number of pages16
JournalExpert Opinion on Drug Discovery
Volume10
Issue number11
DOIs
Publication statusPublished - Nov 2 2015

Fingerprint

Drug Discovery
Osteoporosis
Bone and Bones
Bone Density Conservation Agents
Anabolic Agents
Metabolomics
Bone Remodeling
Expert Testimony
Genomics
RNA Interference
Computational Biology
Mesenchymal Stromal Cells
Proteomics
Molecular Biology
Therapeutics
Economics
Technology
Health
Pharmaceutical Preparations

Keywords

  • bisphosphonates
  • bone remodeling
  • cathepsin K
  • denosumab
  • fractures
  • osteoblast
  • osteoclast
  • osteoporosis
  • sclerostin
  • serms
  • teriparatide

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Gennari, L., Rotatori, S., Bianciardi, S., Gonnelli, S., Nuti, R., & Merlotti, D. (2015). Appropriate models for novel osteoporosis drug discovery and future perspectives. Expert Opinion on Drug Discovery, 10(11), 1201-1216. https://doi.org/10.1517/17460441.2015.1080685

Appropriate models for novel osteoporosis drug discovery and future perspectives. / Gennari, Luigi; Rotatori, Stefano; Bianciardi, Simone; Gonnelli, Stefano; Nuti, Ranuccio; Merlotti, Daniela.

In: Expert Opinion on Drug Discovery, Vol. 10, No. 11, 02.11.2015, p. 1201-1216.

Research output: Contribution to journalArticle

Gennari, L, Rotatori, S, Bianciardi, S, Gonnelli, S, Nuti, R & Merlotti, D 2015, 'Appropriate models for novel osteoporosis drug discovery and future perspectives', Expert Opinion on Drug Discovery, vol. 10, no. 11, pp. 1201-1216. https://doi.org/10.1517/17460441.2015.1080685
Gennari, Luigi ; Rotatori, Stefano ; Bianciardi, Simone ; Gonnelli, Stefano ; Nuti, Ranuccio ; Merlotti, Daniela. / Appropriate models for novel osteoporosis drug discovery and future perspectives. In: Expert Opinion on Drug Discovery. 2015 ; Vol. 10, No. 11. pp. 1201-1216.
@article{b0005febde074d9399a1c476053a2aaa,
title = "Appropriate models for novel osteoporosis drug discovery and future perspectives",
abstract = "Introduction: Osteoporosis is a common skeletal disorder characterized by compromised bone strength and increased fracture risk. It is becoming a growing health-economic problem worldwide. Over the past two decades, there has been considerable progress in the availability of compounds with antiresorptive or anabolic activity on bone. However, existing therapeutic strategies still have limitations.Areas covered: In this review, the authors summarize past and current approaches for the development of antiresorptive and anabolic agents for osteoporosis together with their mechanisms of action. They also provide discussion on the application of new technologies for novel osteoporosis drug discovery.Expert opinion: Thanks to the recent advances in molecular biology over the past few years, novel therapeutic targets for antiresorptive or anabolic compounds have been discovered and several promising new drugs are in preclinical and clinical development. Despite these advances, the current understanding of the mechanisms regulating bone remodeling is far from complete, leaving significant drawbacks to the discovery and the clinical development of novel therapeutic agents. Hopefully, improvements in functional genomics and bioinformatics, along with new technological approaches such as RNA silencing, quantitative proteomics, metabolomics, and the use of mesenchymal stem cells, will address these issues and widen our options for treating several disorders of bone metabolism, including osteoporosis.",
keywords = "bisphosphonates, bone remodeling, cathepsin K, denosumab, fractures, osteoblast, osteoclast, osteoporosis, sclerostin, serms, teriparatide",
author = "Luigi Gennari and Stefano Rotatori and Simone Bianciardi and Stefano Gonnelli and Ranuccio Nuti and Daniela Merlotti",
year = "2015",
month = "11",
day = "2",
doi = "10.1517/17460441.2015.1080685",
language = "English",
volume = "10",
pages = "1201--1216",
journal = "Expert Opinion on Drug Discovery",
issn = "1746-0441",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Appropriate models for novel osteoporosis drug discovery and future perspectives

AU - Gennari, Luigi

AU - Rotatori, Stefano

AU - Bianciardi, Simone

AU - Gonnelli, Stefano

AU - Nuti, Ranuccio

AU - Merlotti, Daniela

PY - 2015/11/2

Y1 - 2015/11/2

N2 - Introduction: Osteoporosis is a common skeletal disorder characterized by compromised bone strength and increased fracture risk. It is becoming a growing health-economic problem worldwide. Over the past two decades, there has been considerable progress in the availability of compounds with antiresorptive or anabolic activity on bone. However, existing therapeutic strategies still have limitations.Areas covered: In this review, the authors summarize past and current approaches for the development of antiresorptive and anabolic agents for osteoporosis together with their mechanisms of action. They also provide discussion on the application of new technologies for novel osteoporosis drug discovery.Expert opinion: Thanks to the recent advances in molecular biology over the past few years, novel therapeutic targets for antiresorptive or anabolic compounds have been discovered and several promising new drugs are in preclinical and clinical development. Despite these advances, the current understanding of the mechanisms regulating bone remodeling is far from complete, leaving significant drawbacks to the discovery and the clinical development of novel therapeutic agents. Hopefully, improvements in functional genomics and bioinformatics, along with new technological approaches such as RNA silencing, quantitative proteomics, metabolomics, and the use of mesenchymal stem cells, will address these issues and widen our options for treating several disorders of bone metabolism, including osteoporosis.

AB - Introduction: Osteoporosis is a common skeletal disorder characterized by compromised bone strength and increased fracture risk. It is becoming a growing health-economic problem worldwide. Over the past two decades, there has been considerable progress in the availability of compounds with antiresorptive or anabolic activity on bone. However, existing therapeutic strategies still have limitations.Areas covered: In this review, the authors summarize past and current approaches for the development of antiresorptive and anabolic agents for osteoporosis together with their mechanisms of action. They also provide discussion on the application of new technologies for novel osteoporosis drug discovery.Expert opinion: Thanks to the recent advances in molecular biology over the past few years, novel therapeutic targets for antiresorptive or anabolic compounds have been discovered and several promising new drugs are in preclinical and clinical development. Despite these advances, the current understanding of the mechanisms regulating bone remodeling is far from complete, leaving significant drawbacks to the discovery and the clinical development of novel therapeutic agents. Hopefully, improvements in functional genomics and bioinformatics, along with new technological approaches such as RNA silencing, quantitative proteomics, metabolomics, and the use of mesenchymal stem cells, will address these issues and widen our options for treating several disorders of bone metabolism, including osteoporosis.

KW - bisphosphonates

KW - bone remodeling

KW - cathepsin K

KW - denosumab

KW - fractures

KW - osteoblast

KW - osteoclast

KW - osteoporosis

KW - sclerostin

KW - serms

KW - teriparatide

UR - http://www.scopus.com/inward/record.url?scp=84946488724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946488724&partnerID=8YFLogxK

U2 - 10.1517/17460441.2015.1080685

DO - 10.1517/17460441.2015.1080685

M3 - Article

C2 - 26292627

AN - SCOPUS:84946488724

VL - 10

SP - 1201

EP - 1216

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 11

ER -